Companies › ImmunityBio
9 active drug programs in 35 registered trials: 22 Phase 2, 12 Phase 1, 1 Phase 3; Oncology, Infectious disease; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Nogapendekin Alfa Inbakicept (N803) Interleukin-15 receptor agonist | IL2RG, IL2RB, IL15RA | Phase 3 | NSCLC Stage IV; Long COVID; Platinum-resistant Ovarian Cancer; Relapsed B-Cell Non Hodgkin Lymphoma … | Mar 2027 |
| M-CENK Autologous engineered NK cells | – | Phase 2 | Platinum-resistant Ovarian Cancer; Metastatic Solid Tumor | May 2027 |
| CD19 t-haNK CAR-T cell therapy targeting CD19 | CD19 | Phase 2 | Relapsed B-Cell Non Hodgkin Lymphoma | May 2027 |
| Aldoxorubicin DNA topoisomerase II alpha inhibitor | TOP2A | Phase 2 | Pancreatic Cancer | May 2027 |
| PD-L1 t-haNK PD-L1-targeted human aNK cell therapy | CD274, PDCD1LG1 | Phase 2 | Pancreatic Cancer; Non-Small Cell Lung Cancer; Glioblastoma; Head and Neck Cancer | May 2027 |
| CD19t-haNK suspension CAR-T cell therapy targeting CD19; engineered NK-92 cell line expressing CD19-directed CAR | CD19 | Phase 1 | Non Hodgkin's Lymphoma Refractory/Relapsed | Mar 2027 |
| IBRX-042 hAd5-based oncolytic virus expressing HPV E6 and E7 epitopes | – | Phase 1 | HPV-Related Carcinoma | Sep 2027 |
| Rituximab (CD19) B-lymphocyte antigen CD20 binding agent | MS4A1 | Phase 1 | Non-Hodgkin Lymphoma Refractory/ Relapsed | Oct 2027 |
| Intravesical Recombinant Mycobacterium (rMBCG) Live attenuated Mycobacterium bovis BCG strain expressing recombinant immunomodulatory pro | – | Phase 1 | NMIBC | Feb 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04505501 | Nogapendekin Alfa Inbakicept (N803) | Phase 2 | HIV/AIDS | Infectious disease | Jun 2025 |
| NCT07108036 | Nogapendekin Alfa Inbakicept (N803) | Phase 2 | Long COVID | Infectious disease | Oct 2026 |
| NCT06161545 | Nogapendekin Alfa Inbakicept (N803) | Phase 2 | Stage II Squamous Cell Carcinoma of the Head and Neck | Oncology | Dec 2026 |
| NCT04340596 | Nogapendekin Alfa Inbakicept (N803) | Phase 1 | HIV Infection | Infectious disease | Dec 2026 |
| NCT06239220 | Nogapendekin Alfa Inbakicept (N803) | Phase 2 | Head and Neck Cancer | Oncology | Dec 2026 |
| NCT06253494 | Nogapendekin Alfa Inbakicept (N803) | Phase 1 | Endometrial Cancer | Oncology | Dec 2026 |
| NCT06239220 | PD-L1 t-haNK | Phase 2 | Head and Neck Cancer | Oncology | Dec 2026 |
| NCT05618925 | CD19t-haNK suspension | Phase 1 | Non Hodgkin's Lymphoma Refractory/Relapsed | Oncology | Mar 2027 |
| NCT07123727 | Nogapendekin Alfa Inbakicept (N803) | Phase 2 | Long COVID | Infectious disease | Mar 2027 |
| NCT05618925 | Nogapendekin Alfa Inbakicept (N803) | Phase 1 | Non Hodgkin's Lymphoma Refractory/Relapsed | Oncology | Mar 2027 |
| NCT06710288 | Nogapendekin Alfa Inbakicept (N803) | Phase 2 | Platinum-resistant Ovarian Cancer | Oncology | May 2027 |
| NCT06710288 | M-CENK | Phase 2 | Platinum-resistant Ovarian Cancer | Oncology | May 2027 |
| NCT07125872 | Nogapendekin Alfa Inbakicept (N803) | Phase 2 | Relapsed B-Cell Non Hodgkin Lymphoma | Oncology | May 2027 |
| NCT07125872 | CD19 t-haNK | Phase 2 | Relapsed B-Cell Non Hodgkin Lymphoma | Oncology | May 2027 |
| NCT04390399 | Nogapendekin Alfa Inbakicept (N803) | Phase 2 | Pancreatic Cancer | Oncology | May 2027 |
| NCT04898543 | Nogapendekin Alfa Inbakicept (N803) | Phase 1 | Metastatic Solid Tumor | Oncology | May 2027 |
| NCT04898543 | M-CENK | Phase 1 | Metastatic Solid Tumor | Oncology | May 2027 |
| NCT04390399 | Aldoxorubicin | Phase 2 | Pancreatic Cancer | Oncology | May 2027 |
| NCT04390399 | PD-L1 t-haNK | Phase 2 | Pancreatic Cancer | Oncology | May 2027 |
| NCT05419011 | Nogapendekin Alfa Inbakicept (N803) | Phase 2 | Colorectal Carcinoma | Oncology | Jul 2027 |
| NCT05976828 | IBRX-042 | Phase 1 | HPV-Related Carcinoma | Oncology | Sep 2027 |
| NCT06334991 | Rituximab (CD19) | Phase 1 | Non-Hodgkin Lymphoma Refractory/ Relapsed | Oncology | Oct 2027 |
| NCT06149481 | Nogapendekin Alfa Inbakicept (N803) | Phase 1 | Metastatic Colorectal Cancer | Oncology | Oct 2027 |
| NCT07085338 | Nogapendekin Alfa Inbakicept (N803) | Phase 2 | Neuroblastoma Recurrent | Oncology | Feb 2028 |
| NCT06800963 | Intravesical Recombinant Mycobacterium (rMBCG) | Phase 1 | NMIBC | Oncology | Feb 2028 |
| NCT07574541 | Nogapendekin Alfa Inbakicept (N803) | Phase 2 | Adenocarcinoma | Oncology | Jun 2028 |
| NCT06745908 | Nogapendekin Alfa Inbakicept (N803) | Phase 3 | NSCLC Stage IV | Oncology | Sep 2028 |
| NCT07686380 | Nogapendekin Alfa Inbakicept (N803) | Phase 2 | Recurrent Prostate Cancer | Oncology | Jan 2029 |
| NCT03022825 | Nogapendekin Alfa Inbakicept (N803) | Phase 2 | Bladder Cancer | Oncology | Mar 2029 |
| NCT03228667 | Nogapendekin Alfa Inbakicept (N803) | Phase 2 | Non-Small Cell Lung Cancer | Oncology | Aug 2029 |
| NCT03228667 | PD-L1 t-haNK | Phase 2 | Non-Small Cell Lung Cancer | Oncology | Aug 2029 |
| NCT06061809 | Nogapendekin Alfa Inbakicept (N803) | Phase 2 | Glioblastoma | Oncology | Dec 2029 |
| NCT06061809 | PD-L1 t-haNK | Phase 2 | Glioblastoma | Oncology | Dec 2029 |
| NCT07355205 | Nogapendekin Alfa Inbakicept (N803) | Phase 1 | Non-small Cell Lung Cancer Stage IV | Oncology | Jul 2032 |
| NCT02138734 | Nogapendekin Alfa Inbakicept (N803) | Phase 1 | Non-muscle Invasive Bladder Cancer | Oncology | Mar 2039 |
Cash and short-term investments of $334m on 2026-09-30; operating cash outflow about $291m a year; runway about 14 months at that burn, to Nov 2027; 6 of 6 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Replimune Fate Therapeutics Arcus Biosciences BioNTech SE Eikon Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.